(ANSA) – ROME, 17 SEPTEMBER – Nerandomilast, an oral inhibitor of phosphodiesterase 4B (Pde4b) still under investigation, could represent a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The experimental Phase III study was the largest trial in idiopathic pulmonary fibrosis (IPF) ever conducted, ongoing at approximately 400 centers and in over 30 countries. For Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim “today’s announcement represents a new step forward in our long history of research in this disease. There are still many unmet needs for patients with idiopathic pulmonary fibrosis and we continue to commit to our research activities in order to develop new therapeutic options for one of the most common interstitial lung diseases”. IPF is one of the most common progressive fibrosing interstitial lung diseases (ILDs), affecting approximately 3 million people worldwide with symptoms such as shortness of breath, dry and persistent cough, chest discomfort, fatigue and weakness. Some of these patients may develop a progressive phenotype known as progressive pulmonary fibrosis (PPF), defined by worsening respiratory symptoms. Boehringer Ingelheim will now submit nerandomilast for approval as a new drug for the treatment of IPF to the US FDA and other health authorities around the world. (ANSA).
2024-09-19 07:40:28